PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that the equation t1/2 = VD / Cl * 0.693 was used
Primary Target and PDB code of Protein-Drug complex
ANTINEOPLASTIC TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) OR AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM) MULTIKINASE TYROSINE KINASE INHIBITOR (FLT3, FLT3 MUTANT KINASES (ITD AND TKD), KIT (WILD TYPE AND D816V MUTANT), PDGFR ALPHA/BETA, VEGFR2, AS WELL AS MEMBERS OF THE SERINE/THREONINE KINASE PKC (PROTEIN KINASE C) FAMILY)
PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that the equation t1/2 = VD / Cl * 0.693 was used
Primary Target and PDB code of Protein-Drug complex
ANTINEOPLASTIC TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) OR AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM) MULTIKINASE TYROSINE KINASE INHIBITOR (FLT3, FLT3 MUTANT KINASES (ITD AND TKD), KIT (WILD TYPE AND D816V MUTANT), PDGFR ALPHA/BETA, VEGFR2, AS WELL AS MEMBERS OF THE SERINE/THREONINE KINASE PKC (PROTEIN KINASE C) FAMILY)
PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that the equation t1/2 = VD / Cl * 0.693 was used
Primary Target and PDB code of Protein-Drug complex
ANTINEOPLASTIC TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) OR AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM) MULTIKINASE TYROSINE KINASE INHIBITOR (FLT3, FLT3 MUTANT KINASES (ITD AND TKD), KIT (WILD TYPE AND D816V MUTANT), PDGFR ALPHA/BETA, VEGFR2, AS WELL AS MEMBERS OF THE SERINE/THREONINE KINASE PKC (PROTEIN KINASE C) FAMILY)
PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that the equation t1/2 = VD / Cl * 0.693 was used
Primary Target and PDB code of Protein-Drug complex
ANTINEOPLASTIC TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) OR AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM) MULTIKINASE TYROSINE KINASE INHIBITOR (FLT3, FLT3 MUTANT KINASES (ITD AND TKD), KIT (WILD TYPE AND D816V MUTANT), PDGFR ALPHA/BETA, VEGFR2, AS WELL AS MEMBERS OF THE SERINE/THREONINE KINASE PKC (PROTEIN KINASE C) FAMILY)